PB0034 - Heparin Induced Thrombocytopenia Before and During COVID-19 Pandemia in Iran

Sunday, July 10, 2022

6:30 PM – 7:30 PM

Location: Exhibition

Presentation Format: In-Person

Co-Author(s)

MA

Minoo Ahmadinejad

Head of reference coagulation laboratory at Iranian Blood Transfusion Organization
Iranian Blood Transfusion Organization and the High Institute for Research and Education
Tehran, Tehran, Iran
MS

Massoumeh Shahbazi

Ph.D. student of Hematology and Blood banking
High Institute for Education and Research in Transfusion Medicine
Tehran, Tehran, Iran
AT

Amir Teimourpour

Bio statistician
Blood Transfusion Research Center, High Institute For Research and Education in Transfusion Medicine, Tehran , Iran
Tehran, Tehran, Iran
MM

Mahsa Mojtabavi Naeini

BS of Chemistry
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Tehran, Tehran, Iran
BA

Bahareh Asadi

BS of Clinical Laboratory Sciences
Blood Transfusion Research Center, High Institute For Research and Education in Transfusion Medicine, Tehran , Iran
Tehran, Tehran, Iran
AR

Ali Rajabi

PhD of Hematology and Blood Banking
Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
Tehran, Tehran, Iran
MJ

Mohammadreza Javan

Msc of Hematology
Blood Transfusion Research Center, High Institute For Research and Education in Transfusion Medicine, Tehran , Iran
Tehran, Tehran, Iran

Presenting Author(s)

PE

Peyman Eshghi

Professor
Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Children’s Health, Shahid Beheshti University of Medical Sciences
Tehran, Tehran, Iran

Background: The patients with COVID-19 disease are at high risk for thrombosis. More aggressive thromboprophylaxis anticoagulation are considered in these patients. Several reports indicates a higher HIT incidence in the patients with COVID-19 than other medical patients,

Aims: We conducted this study to evaluate the frequency of HIT among patients with COVID-19 in comparison with non-COVID-19 patients.

Methods: The study population included patients who referred to the Iranian blood transfusion organization (IBTO) reference coagulation laboratory for anti-PF4/H Ab testing (LFIA method, STic EXPERT, STAGO) during a 30 months period before and after the COVID-19 pandemic in Iran. On 19 February 2020, Iran reported its first confirmed cases of infections in Qom. The patients have been divided into three groups: group1, Sep 2019-Feb 2020 (before COVID-19 pandemic in Iran), group 2: March 2020-Aug 2020 (the first and second peaks), group 3: Sep2020- Feb 2021 (the third and fourth peaks). The demographic data, 4Ts score, Anti PF4-Ab (LIFA), and HIPA test results were evaluated. The HIPA test was checked in cases with the positive result of LFIA test.

Results: A total number of 110 patients have been referred for anti-PF4 Ab testing to our laboratory center during a 30 months period with the detail in table 1and 2.
The rate of positive LFIA was 10 % and 33% in the non-Covid-19 and Covid-19 patients respectively (OR=4.1%, 95% CI, P-value: 0.022). HIPA test was assessed in 4 cases of Covid-19 and all were positive (definitive HIT).

Conclusion(s): Among 110 referral cases in 30 months period who were referred for Anti PF4/H Ab testing to our lab, 94 ( 85%) of cases were referred during the first year of the Covid-19 pandemic in Iran. Regarding the rate of definite HIT (≥16%) among Covid-19 patients, our data confirm the high rate of HIT in this group of patients.